Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kobe University

On March 2, 2026 (the "Termination Date"), Beam Therapeutics Inc. (the "Company") and Bio Palette Co., Ltd. ("Bio Palette") mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the "License Agreement") in connection with the planned dissolution of Bio Palette. The License Agreement was mutually terminated pursuant to a Termination Agreement by and between the Company and Bio Palette dated as of the Termination Date (the "Termination Agreement").

Prior to the execution of the Termination Agreement, Bio Palette and Kobe University ("Kobe") mutually terminated their License Agreement dated May 9, 2017 (the "Kobe-Bio Palette License"), which rendered effective a standby license granted by Kobe to the Company pursuant to the Standby License Agreement between the Company, Bio Palette and Kobe, dated February 9, 2026 (the "Standby License Agreement"). As previously reported, under the Standby License Agreement, to ensure the Company had a continued license in the event of a termination of the Kobe-Bio Palette License, Kobe directly granted the Company an exclusive (even as to Kobe and its affiliates) license of the same scope as the license granted to the Company pursuant to the License Agreement to practice certain of the patents licensed to the Company under the License Agreement, which were licensed to Bio Palette directly from Kobe under the Kobe-Bio Palette License.

Under the License Agreement, the Company (i) received an exclusive, royalty bearing license under certain patent rights related to base editing owned or controlled by Bio Palette to exploit products for the treatment of human disease throughout the world, but excluding products in the microbiome field in Asia and (ii) granted Bio Palette an exclusive, royalty bearing license under certain patent rights related to base editing and gene editing owned or controlled by the Company to exploit products in the microbiome field in Asia.

Pursuant to the Termination Agreement, effective as of the Termination Date, the License Agreement was terminated in its entirety and all of the rights and licenses granted by the parties under the License Agreement terminated in all respects. The Termination Agreement includes a customary mutual release of claims and, following the Termination Date, no future payments shall be due between the Company and Bio Palette under the Termination Agreement or License Agreement.

The foregoing summary of the License Agreement is qualified in its entirety by reference to the full text of the License Agreement, which was filed as Exhibit 10.7 to the Company's Registration Statement on Form S-1, filed on September 27, 2019 and is incorporated herein by reference.